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LETTERS TO THE EDITOR 
ISOLATED MUSICAL OBSESSION 
Dear Sir, 
It was of interest to read the case report on 
musical obsessions (Journal 1999, 41,77-78). The 
clinical picture, especially the phenomenon of a 
particular set of known musical notes repeatedly being 
perceived resembles Palinacousis. This phenomenon 
was descnbed by Jacob and associates in 1973 as 
persistent or recurring paroxysmal auditory illusions 
in which enviornmentally produced auditory 
perceptions persist or recur for a vanable length of 
time after the initial stimulus has ended. These 
palinacoustic events are exact replicas or fragments 
of the original sound. The source may be a voice, 
music or random noises and the sensation is often 
indistinguishable from the original stimulus. They are 
generally neutral in content and characteristically 
occur in the absence of other psychiatric symptoms 
(Malone & Leiman, 1983). Palinacousis is considered 
as a manifestation of temporal lobe dysfunction and 
responds to anticonvulsant medication (Patterson & 
Tomlinson, 1988) 
Awareness of this interesting phenomenon 
of Palinacousis is useful when evaluating symptoms 
of the nature described in the case report. 
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RISPERIDONE IN SCHIZOPHRENIA 
Sir, 
Risperidone is a newer antipsychotic with 
broad spectrum of antipsychotic efficacy and with 
significantly less extrapyramidal side'effects. 
There are plenty of studies reported from western 
countries regarding its efficacy in schizophrenia 
(Mattes, 1997). Till date there are only two clinical 
trials reported from India in schizophrenia 
(Agarwal et al ,1998; Agashe et al.,1999). The 
last article was published in Indian Journal of 
Psychiatry. 1999,41(1), 54-59. This study reports 
significant improvement of both positive and 
negative symptoms with better extrapyramidal 
side effect profiie Since the authors have 
selected both DSM-III-R defined schizophrenia 
patients with duration of illness more than 6 
months and schizophreniform patients with 
duration of illness less than 6 month it is 
premature to conclude risperidone's 
antipsychotic efficacy. As this trial has continued 
upto 4 months many of the cases of 
schizophreniform psychoses would have 
spontaneously remitted. Further discrepancy 
noted in the result is the mention of minimum 
duration of schizophrenic illness as 1 year which 
is contradictory to the inclusion of 
schizophreniform illness. It would have been 
more meaningful if the author's have separately 
analysed the clinical response of schizophrenic 
and schizophreniform patients. A comparative 
analysis of improvement in positive symptoms 
versus negative symptoms may shed more light 
on the differential response of risperidone which 
is not yet studied. Another discrepancy notice in 
the article was the conclusion of significantly less 
extrapyramidal side effects though table 3 of 
adverse effects gives 40% prevalence when 
clubbing, tremor, rigidity, sialorrhoea, oculogyric 
crisis and akatrtisia. From table 2, it is clear that 
extrapyramidal side effects were already present 
in many patients before starting risperidone. 
Hence it is difficult to say that side affects are 
due to risperidone as many of these patients 
were already receiving oral/parenteral 
neuroleptic at the time of intake into the trial. 
Three days stoppage of antipsychotic is not 
enough in the assessment of side effect profile 
especially with depot preparation whose side 
effects can last even for months. 
We conducted an open clinical trial of 
risperidone (6-8 mg/day) on a group of DSM-IV 
defined 24 drug naive schizophernic population 
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for a period of 12 weeks. Risperidone showed 
significant improvement in their positive, 
negative, general psychopathology and 
depressive symptoms when compared with the 
Daseline scores. Comparison of response of 
positive versus negative symptoms did not show 
any significant difference. Assessment ot 
extrapyramidal symptoms using Simpson and 
Angus extrapyramidal symptoms rating scale 
showed high incidence of rigidity (59%), tremor 
(32%), salivation (30%), gait disturbance (25%) 
and akathisia (17%). This high incidence of 
extrapyramidal side effects have not been 
reported earlier though sporadic case reports are 
available from India and abroad (Sureshkumar, 
1999; Rosebush et al, 1997; Faulk et al, 1996). 
As it is a new entrant to the psychiatric 
armamentorium in our country more clinical trials 
are needed to confirm the safety profile of 
risperidone in Indian patients. 
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